Anti-tumour necrosis factor therapy ameliorates joint disease in a chronic model of inflammatory arthritis.
Beech
J T
JT
Thompson
S J
SJ
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D006224:Cricetinae; D004195:Disease Models, Animal; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D007166:Immunosuppressive Agents; D015994:Incidence; D007274:Injections, Intraperitoneal; D007592:Joint Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control; D007719:Knee Joint / Q000473:pathology / Q000503:physiopathology; D051379:Mice; D008811:Mice, Inbred DBA; D012720:Severity of Illness Index; D013729:Terpenes; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D013729:Terpenes; D014409:Tumor Necrosis Factor-alpha; C009042:pristane